Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMO-8400 Extension in Waldenström's Macroglobulinemia
NCT02363439Phase 2Completed
- Sponsor
- Aceragen, Inc.
- Start
- Nov 2014
- Primary completion
- Dec 2016
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
01
Overview
A Phase 2 trial of bazlitoran in Waldenström's macroglobulinemia (WM), sponsored by Aceragen, Inc.. Started Nov 2014; status: completed.
02
Drugs
bazlitoran
03
Conditions
Waldenström's macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT02363439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02363439.